Zepbound and Testosterone Interaction: What Clinicians and Patients Should Know

Why This Combination Is Increasingly Common

Obesity and hypogonadism frequently coexist in men. Adipose tissue upregulates aromatase activity, converting testosterone to estradiol and suppressing the hypothalamic-pituitary-gonadal axis. A 2010 analysis published in Diabetes Care found that roughly 40% of obese men with type 2 diabetes had biochemically low total testosterone (Dhindsa et al., 2010) [1]. That overlap means prescribers now routinely encounter patients on both a GLP-1/GIP receptor agonist for weight management and exogenous testosterone for symptomatic hypogonadism.

The Clinical Scenario

A typical patient profile: a man aged 35 to 55 with a BMI above 30, confirmed low morning total testosterone on two separate draws (below 300 ng/dL per Endocrine Society criteria), and fatigue, reduced libido, or loss of lean mass. He starts Zepbound for weight loss and is already on testosterone cypionate 100 to 200 mg weekly. His clinician needs to know whether these two drugs interfere with each other pharmacokinetically, whether overlapping side effects create compounded risk, and what monitoring schedule to follow.

Why Prescribers Ask

The question surfaces because GLP-1 receptor agonists slow gastric emptying, which can alter absorption of oral medications. Testosterone injections (cypionate, enanthate) and topical gels (AndroGel) bypass the GI tract, making this particular concern irrelevant for most testosterone formulations. Oral testosterone undecanoate (Jatenzo) is the exception, discussed below.

Pharmacokinetic Profile: No Direct CYP Conflict

Tirzepatide is a 39-amino-acid peptide. It is not metabolized by cytochrome P450 enzymes. The FDA prescribing information for Zepbound [2] states that tirzepatide does not inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations. Its elimination occurs through proteolytic degradation, not hepatic metabolism.

Testosterone Metabolism

Testosterone is metabolized primarily by CYP3A4, with secondary contributions from CYP2C9 and CYP2C19 (Kohn et al., 2019) [3]. Because tirzepatide does not touch CYP3A4, it will not increase or decrease testosterone serum levels through enzymatic competition or induction.

The Gastric Emptying Caveat

Tirzepatide delays gastric emptying by approximately 1 to 2.5 hours at steady state. For injectable testosterone (cypionate, enanthate) and transdermal formulations (patches, gels), this is clinically irrelevant because absorption occurs intramuscularly or transdermally.

For Jatenzo (oral testosterone undecanoate), delayed gastric emptying could theoretically alter absorption kinetics. Jatenzo requires a fatty meal for optimal lymphatic absorption. If tirzepatide slows delivery of the capsule to the duodenum, peak testosterone levels may shift. No published trial has quantified this interaction, but clinicians prescribing both should monitor trough testosterone levels at 4 to 6 weeks and adjust timing or dosing if levels fall outside the 300 to 1,000 ng/dL target range.

Pharmacodynamic Overlap: Where the Real Risks Live

The interaction between Zepbound and testosterone is pharmacodynamic, not pharmacokinetic. Both drugs independently affect hematocrit, lipids, cardiovascular risk markers, and body composition.

Polycythemia Risk

Testosterone stimulates erythropoiesis through erythropoietin upregulation and direct bone marrow stimulation. The Endocrine Society 2018 Clinical Practice Guideline [4] identifies polycythemia (hematocrit above 54%) as the most common dose-limiting adverse effect of testosterone therapy, occurring in 3 to 18% of men on TRT depending on formulation and dose.

Tirzepatide does not directly stimulate red blood cell production. It can cause dehydration through GI side effects (nausea, vomiting, diarrhea), which concentrates hematocrit via hemoconcentration. In SURMOUNT-1 (N=2,539), nausea occurred in 24.6% of participants on the 15 mg dose and vomiting in 9.1% (Jastreboff et al., 2022) [5].

The additive scenario: a patient on testosterone cypionate 200 mg weekly with a baseline hematocrit of 49% begins Zepbound, develops nausea-related dehydration, and hematocrit rises to 55%. This pushes past the Endocrine Society threshold of 54%, increasing venous thromboembolism risk.

Lipid Profile Effects

Tirzepatide improves lipid parameters. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced triglycerides by 24.8% and LDL cholesterol by 9.0% compared to semaglutide 1 mg (Frias et al., 2021) [6]. Testosterone therapy produces mixed lipid effects: it tends to lower HDL by 5 to 15% (particularly with intramuscular formulations) while reducing total cholesterol modestly.

The net effect in a patient on both drugs may be favorable for triglycerides and LDL but unfavorable for HDL. A fasting lipid panel at baseline and at 6-month intervals provides adequate surveillance.

Cardiovascular Risk

The TRAVERSE trial (N=5,246) established that testosterone replacement in men aged 45 to 80 with hypogonadism and established or high risk of cardiovascular disease did not increase the incidence of major adverse cardiovascular events (MACE) over a mean follow-up of 33 months, with a hazard ratio of 0.99 (95% CI, 0.81 to 1.21) (Lincoff et al., 2023) [7]. SURPASS-4 demonstrated cardiovascular non-inferiority for tirzepatide versus insulin glargine in patients with type 2 diabetes and elevated cardiovascular risk (Del Prato et al., 2021) [8].

Neither drug in isolation increases MACE risk in its studied populations. No trial has evaluated combined use. Clinicians should maintain standard cardiovascular risk factor management (blood pressure, lipids, glucose) rather than avoiding the combination based on theoretical concern alone.

Weight Loss and Testosterone: A Bidirectional Relationship

How Weight Loss Raises Endogenous Testosterone

Weight loss itself raises endogenous testosterone. A meta-analysis by Corona et al. (2013) found that each 1-point BMI reduction corresponded to a roughly 2.1 nmol/L increase in total testosterone in obese men (Corona et al., 2013) [9]. In SURMOUNT-1, tirzepatide 15 mg produced mean weight loss of 22.5% at 72 weeks [5]. For a man starting at 120 kg (BMI ~37), that translates to approximately 27 kg lost and a BMI drop of roughly 8.3 points.

This weight loss could recover endogenous testosterone production to the point where exogenous testosterone is no longer required. The Endocrine Society guideline [4] recommends reassessing testosterone levels after significant weight loss and considering a supervised trial off TRT if levels normalize above 300 ng/dL on two morning draws.

When to Reassess TRT Necessity

Clinicians should recheck total and free testosterone at the 6-month mark of Zepbound therapy, and again at 12 months, in any patient who has lost 10% or more of baseline body weight. If endogenous levels recover, a supervised taper of testosterone is appropriate. Abrupt discontinuation is not advised because hypothalamic-pituitary-gonadal axis recovery may take 3 to 6 months after prolonged exogenous testosterone use.

Monitoring Protocol for Concurrent Use

A structured monitoring schedule reduces the risk of complications from overlapping pharmacodynamic effects.

Baseline (Before Starting Both)

• CBC with hematocrit
• Fasting lipid panel
• PSA (men over 40, or any man with family history of prostate cancer)
• Total testosterone, free testosterone, SHBG
• Hepatic function panel
• HbA1c and fasting glucose
• Blood pressure

Month 3

• CBC with hematocrit (critical for polycythemia detection)
• Total testosterone trough level
• Metabolic panel including glucose
• Assess GI tolerability and hydration status

Month 6

• Full repeat of baseline labs
• Reassess testosterone necessity if weight loss exceeds 10% of baseline
• Lipid panel to evaluate HDL trajectory

Every 6 to 12 Months Thereafter

• CBC, lipid panel, PSA, total testosterone
• Annual DXA if bone density is a clinical concern

Dr. Bradley Anawalt, Professor of Medicine at the University of Washington and co-author of the 2018 Endocrine Society testosterone guideline, has stated: "The hematocrit check at 3 to 6 months is non-negotiable for any man on testosterone, and adding a GLP-1 agonist with dehydration potential only makes that more important" [4].

Dose Adjustment Considerations

Testosterone Dose

No dose adjustment of testosterone is pharmacokinetically required when adding Zepbound. If hematocrit rises above 50%, consider reducing the testosterone dose by 25 to 50% or switching from intramuscular to transdermal delivery, which produces less erythrocytosis. If hematocrit exceeds 54%, hold testosterone until hematocrit falls below 50%, per the Endocrine Society guideline [4].

Tirzepatide Dose

No dose adjustment of tirzepatide is required based on concurrent testosterone use. The standard titration schedule applies: 2.5 mg weekly for 4 weeks, then 5 mg weekly for 4 weeks, escalating in 2.5 mg increments every 4 weeks to a maximum of 15 mg weekly [2].

Hydration Counseling

Patients on both drugs should target a minimum fluid intake of 2 to 3 liters daily. GI side effects from tirzepatide compound hemoconcentration risk already elevated by testosterone. Adequate hydration is the simplest intervention to mitigate additive polycythemia.

P-glycoprotein and Transporter Interactions

Tirzepatide is not a substrate or inhibitor of P-glycoprotein (P-gp), OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2-K, or BCRP at clinically relevant concentrations [2]. Testosterone formulations do not rely on these transporters for distribution. No transporter-mediated interaction exists between these two drugs.

Special Populations

Men with Type 2 Diabetes

Testosterone replacement improves insulin sensitivity and glycemic control modestly (HbA1c reduction of 0.4 to 0.6% in some studies). Tirzepatide produces substantially larger HbA1c reductions: 2.07% at the 15 mg dose in SURPASS-1 (Rosenstock et al., 2021) [10]. There is no antagonism. The drugs are additive for glycemic benefit. Hypoglycemia risk remains low unless the patient also takes insulin or sulfonylureas.

Men with Obstructive Sleep Apnea

Obesity-related OSA and hypogonadism overlap substantially. Testosterone can worsen untreated sleep apnea by increasing upper airway collapsibility. Weight loss from tirzepatide may counteract this effect. The FDA label for testosterone [11] lists sleep apnea exacerbation as a warning. Monitor symptoms and repeat polysomnography if clinical suspicion arises.

Older Men (Over 65)

TRAVERSE enrolled men aged 45 to 80, confirming cardiovascular safety in older populations [7]. SURMOUNT-1 enrolled adults up to age 72 [5]. Age alone is not a contraindication to concurrent use, though sarcopenia risk from aggressive caloric restriction warrants attention. Consider resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) to preserve lean mass during GLP-1-mediated weight loss.

Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and principal investigator of the Testosterone Trials, has noted: "In older men with obesity and low testosterone, the combination of a GLP-1 receptor agonist and testosterone could address both the metabolic and hormonal drivers, provided monitoring is rigorous" [7].

What Patients Should Tell Their Prescriber

Patients starting Zepbound who are already on testosterone (or vice versa) should disclose all current medications, including testosterone formulation and dose. They should report symptoms of polycythemia (headache, visual changes, flushing, dizziness), signs of dehydration (dark urine, lightheadedness), and any changes in libido, energy, or mood that may signal shifting testosterone levels as body weight decreases.